about
The evolving role of response-adapted PET imaging in Hodgkin lymphomaThe role of FDG-PET in defining prognosis of Hodgkin lymphoma for early-stage diseaseBrentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers.Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin's lymphoma with an emphasis on targeted therapies and transplantation strategiesLong-term survival in young and middle-aged Hodgkin lymphoma patients in Sweden 1992-2009-trends in cure proportions by clinical characteristics.Secondary cancer in a survivor of Hodgkin's lymphoma: A case report and review of the literature.Suppressor of cytokine signaling 1 gene mutation status as a prognostic biomarker in classical Hodgkin lymphoma.Fertility status of Hodgkin lymphoma patients treated with chemotherapy and adjuvant gonadotropin-releasing hormone analoguesInvolved site radiation therapy for the treatment of early-stage Hodgkin lymphoma in adolescents and young adultsGlucocorticoids enhance the in vivo migratory response of human monocytesComparing the accuracy of quantitative versus qualitative analyses of interim PET to prognosticate Hodgkin lymphoma: a systematic review protocol of diagnostic test accuracy.Brentuximab vedotin followed by ABVD +/- radiotherapy in patients with previously untreated Hodgkin lymphoma: final results of a pilot phase II study.Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience.FDG PET/CT imaging as a biomarker in lymphoma.Current role of autologous and allogeneic stem cell transplantation for relapsed and refractory hodgkin lymphoma.Increased healthcare use up to 10 years among relapse-free Hodgkin lymphoma survivors in the era of intensified chemotherapy and limited radiotherapy.Primary refractory and early-relapsed Hodgkin's lymphoma: strategies for therapeutic targeting based on the tumour microenvironment.The new therapeutical scenario of Hodgkin lymphoma.Microenvironment-related biomarkers and novel targets in classical Hodgkin's lymphoma.Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.High-throughput sequencing for noninvasive disease detection in hematologic malignancies.Detection and prognostic value of recurrent exportin 1 mutations in tumor and cell-free circulating DNA of patients with classical Hodgkin lymphoma.Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.Mechanisms underlying the association between obesity and Hodgkin lymphoma.Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis.Dual PI3K/ERK inhibition induces necroptotic cell death of Hodgkin Lymphoma cells through IER3 downregulation.A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation.Hodgkin's Lymphoma - evaluation of patients submitted to Autologous transplantation of hematopoietic cells in the Hematology Service of the Hospital Walter Cantídio - Fortaleza, Brazil.Phase II study of interim PET-CT-guided response-adapted therapy in advanced Hodgkin's lymphoma.The role of FDG-PET in Hodgkin lymphomaHigh frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center.Caecal leiomyoma detected by whole-body MRI in a patient with Hodgkin lymphoma: first case report.Recent Advances of Cell-Cycle Inhibitor Therapies for Pediatric Cancer.PET/CT in the Evaluation of Relapsed or Refractory Hodgkin Lymphoma.Chromosomal Instability in Hodgkin Lymphoma: An In-Depth Review and Perspectives.FOXC1, the new player in the cancer sandbox.Pembrolizumab and its role in relapsed/refractory classical Hodgkin's lymphoma: evidence to date and clinical utility.Response to the letter by Adams and Kwee, entitled: "Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma".Long-term follow up of Hodgkin lymphoma.Impact of Provider Volume on Outcomes of Patients With Hodgkin Lymphoma.
P2860
Q26750993-65D11F01-187E-422C-AB5D-D97427A0DF87Q26858893-30535F67-2862-4847-A081-C60ECEEA708FQ33420273-F02B5863-9E64-4C29-96B9-5A6C95DEF681Q33886267-AFD6AFD2-A183-486E-A2A6-10A32E20314DQ34672857-95363C64-15B1-49EF-B028-029F9CC5E32DQ34993823-3F4BB5FF-C2E9-4CBC-8719-A8FEF988B7F9Q35763914-45F8D84D-224F-4BA2-93EA-CC78C497F7A2Q36010259-A8812B73-3214-4A84-9F6F-C792A199EB2FQ36450854-19CA3412-A536-435D-9430-6AE811E1B2A2Q36788633-B1FE628F-3B77-4CDC-85BA-9BBD6E32197EQ37178329-92B5D88C-0DDD-47C4-B5B3-F6DF4AAD6B89Q37216325-D94C19EF-D73A-437D-B1B7-3749A49F083DQ37563122-841B8D2B-5510-4774-B8BE-CB52D8358935Q38312367-091FA5B8-4E4E-4136-849F-152631687E5CQ38368587-61EA605F-223E-40A1-AF0D-145E9078CBBCQ38403661-DAC53A45-FC75-456E-AE5E-6F4F052B4016Q38466376-74EAA330-2B7E-4311-9BB7-DC8E9FBBBA4CQ38513816-F5F4C71D-EEAB-447D-9AE0-585C5124F4E5Q38557033-21DC715D-63D9-4905-8E49-CB91CC345B36Q38664909-F3DA142E-A54D-4843-9F1A-5B8D89464590Q38672646-23F3D00A-F8DD-47BE-AF0D-D6A5A2CAD4EDQ38754419-3D111FBB-D120-4040-B328-7C23A3C8A1A7Q38850144-3517A662-CAD1-41FA-A426-E747FAF6CD15Q38910560-83627D18-AE00-479E-B5B0-A57BC59FE2EDQ38929198-B384F757-52AC-45F1-829F-25C38AC92011Q39263090-019FEA5F-D8B4-4DF0-9655-253A1E182B7EQ40421108-7174069D-65D8-4E8E-9EFA-7AF321BA3366Q40422018-721CF422-3430-4EDA-B666-6D63BCA338ADQ41378943-037A9EF4-C494-40CC-B0D3-56772D8A39F5Q41691698-4A59AFC5-E2B9-4567-AB32-54EF25D46810Q46879226-1B72FA7F-B749-40B4-B9F9-0494EA4072C8Q47133349-A06753F0-4696-47AD-9B74-0A9B2BA23941Q47447546-0C23AE26-E366-40FA-BCEC-DA9F8727220CQ49764261-9F2972A1-7CF0-49E9-95B3-FB319A138A40Q52340211-6DA782A0-B3CE-43C5-B08E-914745E724FCQ52682253-2EEA3A05-2496-4BE1-91F9-499D1D6C0347Q52721221-2698CAC6-198B-4A1D-8760-944D317D402FQ52937933-B8D16DAB-F09C-4EB6-87BE-6CB78D066599Q55002602-C1A861F7-27F0-4BCF-9AA1-768DCA6D539FQ55435299-E202EA3F-9CD0-4AAA-9E6E-5E999F874819
P2860
description
2014 nî lūn-bûn
@nan
2014 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Treatment of Hodgkin lymphoma: a 50-year perspective.
@ast
Treatment of Hodgkin lymphoma: a 50-year perspective.
@en
Treatment of Hodgkin lymphoma: a 50-year perspective.
@nl
type
label
Treatment of Hodgkin lymphoma: a 50-year perspective.
@ast
Treatment of Hodgkin lymphoma: a 50-year perspective.
@en
Treatment of Hodgkin lymphoma: a 50-year perspective.
@nl
prefLabel
Treatment of Hodgkin lymphoma: a 50-year perspective.
@ast
Treatment of Hodgkin lymphoma: a 50-year perspective.
@en
Treatment of Hodgkin lymphoma: a 50-year perspective.
@nl
P2093
P356
P1476
Treatment of Hodgkin lymphoma: a 50-year perspective.
@en
P2093
George P Canellos
Jonathan W Friedberg
Saul A Rosenberg
T Andrew Lister
Vincent T Devita
P304
P356
10.1200/JCO.2013.53.1194
P407
P577
2014-01-01T00:00:00Z